we invest in
We offer support to young companies developing breakthrough products and services in a range of industries. From the Internet of Things to Artificial Intelligence, From Cleantech to Life Sciences, we work with founders to transform visionary concepts into products at the leading edge of their respective markets.
not just investors
When ZFHN agrees to an investment, we don’t dictate terms, nor do we leave young companies to figure things out on their own. We become partners with the founder and his or her team. We listen to their visions, ideas, and plans. We offer expert advice, contacts, and the reassurance that we are committed to a long-term relationship. We continue to provide support until founders are ready to go it alone.
A City That Values Entrepreneurship and Tradition
Heilbronn has been a trading crossroads since the Middle Ages, and area residents are known today for their can-do attitude. Innovators begin young here, at the Experimenta Theme Park, and can find excellent institutions of higher learning right in Heilbronn. Traditions – including the wine festivals held at vineyards just outside the city – are cherished by residents new and old.
Long-term partners with a passion for excellence
ZFHN’s team members have spent decades, collectively, supporting startups from the seed-funding stage on through to market entry and successful exit. Since our founding in 2006, we have built a diversified team of specialists. All team members are passionately committed to achieving outstanding results for our partners – the companies we invest in.
BORN2GROW Seedfonds and High-Tech Gründerfonds on board as investors Karlsruhe/Heilbronn/Bonn, 5 February 2018. Karlsruhe-based LightnTec GmbH, a developer and manufacturer of digital light and its illumination on thin film for innovative indoor and outdoor advertising spaces as well as digital lighting systems, has successfully completed an additional financing round. A seven-figure investment sum was raised [...]
The Wohlgelegen-Turm was the meeting place for international representatives from politics and business as well as from the investment companies of the ZFHN. Thomas R. Villinger, CEO of ZFHN, announced further investments for the upcoming year and was optimistic about the further development of the fund and its investments. Villinger also took a look into [...]
Greenovation Biotech GmbH reports positive clinical data from the Phase 1 safety study for moss-aGal
In October, Greenovation Biotech GmbH successfully completed the Phase I study of moss-aGal for the treatment of Fabry disease (FD). The results of the study indicate that moss-aGal has an excellent safety profile at the tested dose of 0.2 mg / kg body weight. The single-dose study was planned for patients suffering from FD. Therefore, [...]